SCHEMBL24933208

SCHEMBL24933208

CS(=O)(=O)NCc1ccc(-c2cc(C(N)=O)c(=O)[nH]c2C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.40
NEK1 Q96PY6 1/20 0.39
HSD17B1 P14061 5/20 0.39
HSD17B2 P37059 5/20 0.39
SCN9A Q15858 2/20 0.38
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
KIF11 P52732 1/20 0.36
GRIA2 P42262 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.36
ALOX5 P09917 1/20 0.35
S1PR1 P21453 1/20 0.35
BTK Q06187 1/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933209 0.84 HSD17B1 (0.39) HSD17B1HSD17B2BTK
SCHEMBL24933588 0.84 CHUK (0.49) HSD17B1HSD17B2BRD4KIF11
SCHEMBL24933771 0.83 IKBKB (0.42) HSD17B1HSD17B2KIF11KDM4E
SCHEMBL24933797 0.80 PARP1 (0.44) HSD17B1HSD17B2
SCHEMBL24933189 0.80 HSD17B1 (0.39) HSD17B1HSD17B2BTK
SCHEMBL24933359 0.79 HSD17B2 (0.50) HSD17B1HSD17B2BTK
SCHEMBL24933350 0.78 RXRA (0.37) KMT2ANEK1HSD17B1HSD17B2
SCHEMBL24933605 0.78 HSD17B2 (0.41) HSD17B1HSD17B2KIF11
SCHEMBL24933312 0.78 BTK (0.42) KMT2AHSD17B1HSD17B2KDM4EBTK
SCHEMBL24933339 0.77 HSD17B1 (0.41) HSD17B1HSD17B2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed